Please assess the completion status of the following clinical trial:

Trial Title: Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men aged 18-60 years~* BMI \> 20kg/m2 and \<35kg/m2~Exclusion Criteria:~* Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months of the study~* Use of GH or growth hormone stimulating peptides within six months of starting the study~* Change in lipid lowering or antihypertensive regimen within 3 months of screening~* Fasting blood sugar \> 126 mg/dL, SGOT \> 2.5 times ULN, Hgb \< 12.0 g/dL, creatinine \> 1.4 mg/dL~* Carpal tunnel syndrome~* Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer~* For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5 ng/mL~* Prior history of hypopituitarism, head irradiation or any other condition known to affect the GH axis~* Weight \< 110 lbs.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Growth Hormone Releasing Hormone (Type: EXPERIMENTAL): Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).